Results 61 to 70 of about 14,325 (202)

Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study. [PDF]

PLoS ONE, 2013
Patients with chronic kidney disease (CKD) have high cardiovascular mortality and morbidity associated with increased arterial stiffness. Plasma aldosterone levels are increased in CKD, and aldosterone has been found to increase vascular inflammation and
Lene Boesby, Thomas Elung-Jensen, Svend Strandgaard, Anne-Lise Kamper   +3 more
doaj   +1 more source

Effect of eplerenone on aldosterone and von Willebrand factor levelsin patients with myocardial infarction and chronic kidney disease

Zaporožskij Medicinskij Žurnal, 2022
Aim: to study the levels of aldosterone and von Willebrand factor (VWF) in patients with Q-wave acute myocardial infarction (Q-AMI) and underling chronic kidney disease (CKD) using aldosterone antagonists. Materials and methods.
V. K. Tashchuk, O. S. Polianska, O. I. Hulaha   +2 more
doaj   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

ESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann‐Kathrin Schäfer, Michael J. Koziolek, Manuel Wallbach   +9 more
wiley   +1 more source

Aldosterone as a renal growth factor [PDF]

, 2010
Aldosterone regulates blood pressure through its effects on the cardiovascular system and kidney. Aldosterone can also contribute to the development of hypertension that leads to chronic pathologies such as nephropathy and renal fibrosis.
Dooley, Ruth, Harvey, Brian J, Thomas, Warren   +2 more
core   +1 more source

Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction

European Journal of Heart Failure, EarlyView.
Summary of the machine learning clustering methodology and results of the study. Clusters are identified using machine learning approach in the learning set population evaluating specific combinations of multiple characteristics. Then identified clusters are predicted and tested in the learning set to evaluate their association with outcomes.
Luca Monzo, Emmanuel Bresso, Kenneth Dickstein, Bertram Pitt, John G.F. Cleland, Stefan D. Anker, Carolyn S.P. Lam, Mandeep R. Mehra, Dirk J. van Veldhuisen, Barry Greenberg, Faiez Zannad, Nicolas Girerd   +11 more
wiley   +1 more source

Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups

Frontiers in Pharmacology
Introduction: Eplerenone is approved for the treatment of hypertension as well as symptomatic heart failure with reduced ejection fraction (HFrEF) following an acute myocardial infarction.
Xin Guan, Yusi Yang, Xinru Li, Yue Feng, Jizhen Li, Xuewen Li   +5 more
doaj   +1 more source

Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial

European Journal of Heart Failure, EarlyView.
ABSTRACT Aims Anaemia is common in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and associated with poor clinical outcomes. While renin–angiotensin system blockers reduce haemoglobin, little is known about the effect of mineralocorticoid receptor antagonists on haemoglobin and in patients with anaemia.
Misato Chimura, Mingming Yang, Alasdair D. Henderson, Pardeep S. Jhund, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Gerasimos Filippatos, Grzegorz Gajos, Katharina Mueller, Andrea Glasauer, Katja Rohwedder, Prabhakar Viswanathan, Carolyn S.P. Lam, Naoki Sato, Michele Senni, Adriaan A. Voors, Faiez Zannad, Mehmet B. Yilmaz, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray, on behalf of the FINEARTS‐HF Committees and Investigators   +23 more
wiley   +1 more source

Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy

Frontiers in Pharmacology, 2021
Purpose: To evaluate efficacy of eplerenone therapy vs. observation on resolution of subretinal fluid (SRF) in patients with acute and chronic central serous chorioretinopathy (CSCR) in routine clinical practice.Methods: Retrospective comparative case ...
Katrin Fasler, Katrin Fasler, Jeanne M. Gunzinger, Jeanne M. Gunzinger, Daniel Barthelmes, Daniel Barthelmes, Daniel Barthelmes, Sandrine A. Zweifel, Sandrine A. Zweifel   +8 more
doaj   +1 more source

Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post‐hoc analysis of the ROTATE ‐3 study [PDF]

, 2023
Tom T. G. F. Lieverse, María Jesús Puchades, Douwe J. Mulder, Michele Provenzano, Guido Krenning, Niels Jongs, Simon E. Wink, Riemer H. J. A. Slart, Michele Andreucci, Luis D’Marco, Luca De Nicola, José Luis Górriz, Hiddo J.L. Heerspink   +12 more
openalex   +1 more source

Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]

, 2017
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Jhund, Pardeep S., Køber, Lars, McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +3 more sources